[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Università Politecnica delle Marche\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":112},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,71,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100635272","role-of-medical-thoracoscopy-in-pleural-infection-prompt-trial-100635272",false,"NCT07550530","Role of Medical Thoracoscopy in Pleural Infection (PROMPT Trial)","Multicentre Prospective Comparative Study of Medical Thoracoscopy vs Standard of Care in the Management of Pleural Infection","PROMPT","Inclusion criteria\n\n* Adults ≥ 18 years\n* Clinical and radiological diagnosis of pleural infection (purulent, culture-positive, or pH \\\u003C 7.2)\n* Need of pleural drainage\n* Able and willing to give informed consent\n\nExclusion criteria\n\n* Chest drain in situ \\>24h before randomisation\n* Post-traumatic pleural effusion\n* Known allergy to fibrinolytic agents or contraindication to thoracoscopy\n* Pregnancy or breastfeeding\n* Life expectancy \\\u003C 3 months from another illness\n* Previous lung surgery (pneumonectomy) in the same side of pleural infection\n* Previous pleurodesis in the same side of pleural infection\n* Any contraindication to Medical thoracoscopy","ALL","18 Years",{"count":20,"type":21},170,"ESTIMATED","INTERVENTIONAL",[24],"NA","The PROMPT study is testing whether an early keyhole procedure called Medical Thoracoscopy, which lets doctors look inside the chest and remove infected fluid, works better than current standard treatment (medicines to break up thick fluid) for people with pleural infection. About 170 patients in several hospitals will be randomly assigned to one of the two treatments, and researchers will see which approach results in fewer additional procedures-such as another drain or surgery-within 30 days, as well as how quickly people recover and whether they experience any complications. Everyone in the study receives high-quality care, and the results will help doctors better understand which treatment gives patients the best chance of recovering quickly and safely",[27,28,29],"Pleural Infection","Pleural Infections","Pleural Infections and Inflammations",[31,32,33],"Pleural infection","Medical Thoracoscopy","Trial","NOT_YET_RECRUITING","2026-04-21",{"date":37,"type":38},"2026-04-24","ACTUAL",{"date":40,"type":21},"2026-11-01",{"date":42,"type":21},"2029-03-31",{"name":44,"class":45},"Università Politecnica delle Marche","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100631340","evaluation-of-the-microcirculatory-response-to-fluids-in-critically-ill-patients-with-venous-congestion-a-prospective-observational-study-100631340","NCT07499401","Evaluation of the Microcirculatory Response to Fluids in Critically Ill Patients With Venous Congestion: A Prospective Observational Study","MICRO-CONGEST","Inclusion Criteria:\n\n* Critically ill patients admitted to the intensive care unit\n* Invasive or minimally invasive hemodynamic monitoring\n\nExclusion Criteria:\n\n* Suspected or confirmed pregnancy\n* Inability to access the oral cavity (e.g., facial trauma, oral bleeding)",{"count":54,"type":21},30,"OBSERVATIONAL","The hypothesis is that fluid-responsive patients who show signs of venous congestion experience a worsening of microcirculatory status after fluid administration compared to patients without signs of venous congestion",[58,59,60],"Venous Congestion","Microcirculation","Volume Expansion","RECRUITING","2026-03-28",{"date":64,"type":38},"2026-04-02",{"date":66,"type":38},"2024-12-15",{"date":68,"type":21},"2026-06",{"name":44,"class":45},1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":70},"100631339","assessment-of-venous-return-during-volume-expansion-a-prospective-observational-study-100631339","NCT07499388","Assessment of Venous Return During Volume Expansion: a Prospective Observational Study","PSM-PVC-RITVEN","Inclusion Criteria:\n\n* Critically ill patients admitted to the intensive care unit\n* Invasive or minimally invasive hemodynamic monitoring\n* Clinical indication for volume expansion with 500 mL of crystalloids\n\nExclusion Criteria:\n\n* Suspected or confirmed pregnancy\n* Clinical conditions that may reduce the reliability of hemodynamic monitoring:\n* Severe aortic stenosis or regurgitation\n* Severe mitral stenosis or regurgitation\n* History of peripheral arterial disease\n* Clinical contraindications to the supine position",{"count":79,"type":21},45,"According to Guyton's model of venous return, the fluids that effectively increase cardiac output are those that, once administered, increase the vascular stressed volume, thereby increasing the mean systemic filling pressure (Pms) without increasing the central venous pressure (CVP). In this way, since the gradient between Pms and CVP increases, venous return-and consequently cardiac output-also increases.\n\nIn cases where physiologically ineffective fluids are administered, the situation arises in which, in addition to increasing the stressed volume and thus Pms, CVP also increases. As a result, the gradient between Pms and CVP remains unchanged, and cardiac output does not increase.\n\nThe hypothesis is that only a portion of the fluids administered during volume expansion are actually effective in increasing the gradient between Pms and CVP.",[82],"Hemodynamic Changes","2026-03-23",{"date":85,"type":38},"2026-03-30",{"date":87,"type":38},"2025-03-01",{"date":89,"type":21},"2026-07",{"name":44,"class":45},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":4},"100607512","1-safe-ai-onco-track-multimodal-genai-for-early-detection-of-minimal-residual-disease-and-recurrence-in-gastrointestinal-oncology-100607512","NCT07189520","1. SAFE-AI ONCO-TRACK: Multimodal GenAI for Early Detection of Minimal Residual Disease and Recurrence in Gastrointestinal Oncology","SAFE-AI ONCO-TRACK: Multimodal GenAI for Early Detection of Minimal Residual Disease and Recurrence in Gastrointestinal Oncology","ONCO-TRACK","Inclusion Criteria (Justification in parenthesis):\n\n* Age ≥18 years (RC and EC are primarily adult-onset cancers, and adult inclusion aligns with ethical biospecimen collection and consent processes.)\n* Histologically confirmed diagnosis of rectal or esophageal cancer (Confirms clinical relevance and eligibility for standard treatment pathways.)\n* Treatment plan includes surgical resection with curative intent (Ensures applicability to MRD and outcome prediction tasks.)\n* Undergoing standard-of-care neo-adjuvant or perioperative therapy (Ensures data consistency and relevance to response modelling.)\n* Ability and willingness to provide informed consent for biospecimen and clinical data use (Meets ethical requirements for participation.)\n* Availability for longitudinal blood sampling at T0 (baseline), T1 (3 months post-treatment), and T2 (6 months post-treatment) (Critical for temporal biomarker analysis.)\n* Optional Inclusion: Access to tumor tissue (archival or fresh) for multi-omic profiling (Supports deep integrative biomarker discovery.)\n\nExclusion Criteria:\n\n* Diagnosis of non-resectable or metastatic disease at enrollment (Excludes non-curative settings where the longitudinal biomarker protocol may not be feasible.)\n* Emergency surgeries or treatment plans that deviate from standard protocols (To maintain data comparability.)\n* Inability or refusal to provide informed consent (Essential for ethical compliance.)\n* Failure to complete biospecimen donation or key follow-up timepoints (Maintains data integrity and model reliability.)",{"count":100,"type":21},700,"Current decision tools (TNM, MRI\u002FPET, CEA, and other serum markers, as well as single-marker genomics) are insufficiently predictive of responders, fail to detect early MRD in many cases, and rarely connect molecular biology to dynamic perioperative data. SAFE-AI will build and validate multimodal, explainable GenAI models that fuse liquid\u002Ftissue multi-omics with radiology and clinical trajectories to:\n\n(i) detect MRD earlier, (ii) improve recurrence-risk calibration, and (iii) support non-invasive \"virtual biopsy\"-inferring tissue-level features from blood profiles, and vice-versa, to mitigate missing-modality gaps. This is grounded in the strong mechanistic premise that integrating heterogeneous molecular signals with imaging captures tumour-host biology more completely than single-modality assays, enabling actionable, calibrated risk estimates for rectal and oesophageal cancer.\n\nThe clinical hypothesis is that such integrated models can improve recurrence prediction by at least 20% over guideline baselines, with transparent uncertainty and bias monitoring to meet EU AI Act\u002FMDR expectations.",[103],"Rectal Cancer","2025-09-16",{"date":106,"type":38},"2025-09-24",{"date":108,"type":21},"2026-06-01",{"date":110,"type":21},"2030-06-01",{"name":44,"class":45},""]